Zdrowie i gospodarka · 13/01/1999
FDA Approves Selegiline Hydrochloride Tablets for Dogs with Cognitive Dysfunction Syndrome
The FDA is amending its animal drug regulations to reflect approval of a supplemental new animal drug application filed by Pfizer, Inc. for selegiline hydrochloride tablets to treat cognitive dysfunction syndrome in dogs.
Source: Federal Register — Food and Drug AdministrationOpen original release →